Influence of data disclosures on physician decisions about off-label uses: findings from a qualitative study
Open Access
- 19 April 2022
- journal article
- research article
- Published by Springer Nature in BMC Primary Care
- Vol. 23 (1) , 1-9
Abstract
Prescribing approved products for unapproved uses (off-label use) is not uncommon among physicians in certain medical specialties. Available evidence about an off-label use – both supportive and unsupportive – can influence prescribers’ decisions about a drug’s appropriateness for a particular case. The objectives of this study were: (1) to examine physician perceptions about off-label uses generally, including their awareness of unsupportive data; and (2) to explore the influence of disclosure information about unsupportive data on off-label prescribing decisions. Semi-structured interviews were conducted between December 2019 and January 2020 with oncologists (n = 35) and primary care physicians (n = 35). Interviews explored general prescribing practices, understanding of and information sources for learning about off-label use of prescription drugs, awareness of unsupportive data related to off-label uses, and preferences and reactions to disclosure statements about the existence of unsupportive data related to an off-label use. Most participants reported prescribing drugs for off-label uses (with half reporting regular off-label prescribing). However, among those who prescribe off-label, approximately two-thirds had never seen unsupportive data about off-label uses. Physicians preferred a disclosure statement that provided a summary of the unsupportive data about the off-label use; this statement also led most physicians to say they were unlikely or less likely to prescribe the drug for that use. This study suggests that physicians’ decision-making about prescribing for off-label uses of approved drugs may be influenced by awareness of unsupportive data. Our interviews also suggest that providing more information about unsupportive study findings may result in a reduction in reported prescribing likelihood.Keywords
This publication has 26 references indexed in Scilit:
- Ten Common Questions (and Their Answers) About Off-label Drug UseMayo Clinic Proceedings, 2012
- A Randomized Study of How Physicians Interpret Research Funding DisclosuresNew England Journal of Medicine, 2012
- A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus GoldstandardPLOS ONE, 2012
- What's Keeping Us So Busy in Primary Care? A Snapshot from One PracticeNew England Journal of Medicine, 2010
- Factors Associated With Physicians’ Reliance on Pharmaceutical Sales RepresentativesAcademic Medicine, 2009
- Off-Label Prescribing to Children in the United States Outpatient SettingAcademic Pediatrics, 2009
- Off-Label Prescribing: A Call for Heightened Professional and Government OversightJournal of Law, Medicine & Ethics, 2009
- How numeracy influences risk comprehension and medical decision making.Psychological Bulletin, 2009
- The information‐seeking behaviour of doctors: a review of the evidenceHealth Information and Libraries Journal, 2007
- Publication bias in clinical researchThe Lancet, 1991